Cohort profile: l’Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada
Open Access
Abstract
Purpose: Thel’Actuel PrEP Cohortwas established to monitor the uptake, effectiveness, safety and changes in sexual risk behaviours among individuals receiving pre-exposure prophylaxis (PrEP) for the prevention of HIV. This prospective dynamic cohort is based at Clinique médicale l’Actuel, a large sexual health clinic located in Montreal, Canada.Participants: Since the cohort inception in January of 2013 through June 2018, 2156 individuals consulted for PrEP as participants in the l’Actuel PrEP Cohort. Median age was 35 years (IQR: 29–44 years) and the majority (96%) were men who have sex with men. Among 1551 individuals who initiated PrEP care, the median duration of follow-up was 9.2 months (IQR: 3.7–19.6), with substantial variation based on year of cohort entry. Thel’Actuel PrEP Cohortcontains both daily and intermittent ‘on-demand’ PrEP users and has the largest reported population of intermittent PrEP users (n=406) in North America.Findings to date: No incident HIV infections have occurred among individuals using PrEP over 1637 person-years of follow-up. However, retention in PrEP care is essential as three individuals who discontinued PrEP subsequently acquired HIV, translating to an HIV incidence of 3.9 cases per 100 person-years (95% CI: 1.3 to 12.1). Among a sample of participants with 1 year of follow-up before and after PrEP initiation (n=109), a moderate increase in sexually transmitted infections was observed following PrEP start.Future plans: Thel’Actuel PrEP Cohortcontinues to grow with new participants starting PrEP monthly and extended follow-up for existing users. The cohort data will be used for ongoing monitoring of PrEP and for population-level modelling of the impact of PrEP on HIV incidence in Montreal.Keywords
This publication has 23 references indexed in Scilit:
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2016
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 InfectionNew England Journal of Medicine, 2015
- Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American CohortPLOS ONE, 2015
- Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM)AIDS and Behavior, 2015
- Predictors of interest in taking pre‐exposure prophylaxis among men who have sex with men who used a rapid HIV‐testing site in Montreal (Actuel sur Rue)HIV Medicine, 2015
- Will Risk Compensation Accompany Pre-Exposure Prophylaxis for HIV?AMA Journal of Ethics, 2014
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Antiretroviral Preexposure Prophylaxis for HIV PreventionNew England Journal of Medicine, 2013
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010